Benzothieno[3,2-c]pyridines as &agr;2 antagonists
    8.
    发明授权
    Benzothieno[3,2-c]pyridines as &agr;2 antagonists 有权
    苯并噻吩并[3,2-c]吡啶作为α2拮抗剂

    公开(公告)号:US06426350B1

    公开(公告)日:2002-07-30

    申请号:US09806432

    申请日:2001-03-30

    IPC分类号: C07D49504

    CPC分类号: C07D495/04

    摘要: The present invention concerns the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein each R1 is independently hydrogen, halogen, C1-6alkyl, nitro, hydroxy or C1-4alkyloxy; Alk is C1-6alkanediyl; n is 1 or 2; p is 0, 1 or 2; D is an optionally substituted mono-, bi- or tricyclic nitrogen containing heterocycle having central &agr;2-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine.

    摘要翻译: 本发明涉及配制N-氧化物的化合物,其药学上可接受的加成盐和立体化学异构形式,其中每个R 1独立地是氢,卤素,C 1-6烷基,硝基,羟基或C 1-4烷氧基; Alk是C1-6烷二基; n为1或2; p为0,1或2; D是具有中枢性α2-肾上腺素受体拮抗剂活性的任选取代的单环,双环或三环含氮杂环。 它还涉及它们的制备,包含它们的组合物及其作为药物的用途。

    Benzothieno[3,2-c]pyridines as &agr;2 antagonists
    9.
    发明授权
    Benzothieno[3,2-c]pyridines as &agr;2 antagonists 有权
    苯并噻吩并[3,2-c]吡啶作为α2拮抗剂

    公开(公告)号:US06774129B2

    公开(公告)日:2004-08-10

    申请号:US10123338

    申请日:2002-04-16

    IPC分类号: C07D49504

    CPC分类号: C07D495/04

    摘要: The present invention concerns the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein each R1 is independently hydrogen, halogen, C1-6alkyl, nitro, hydroxy or C1-4alkyloxy; Alk is C1-6alkanediyl; n is 1 or 2; p is 0, 1 or 2; D is an optionally substituted mono-, bi- or tricyclic nitrogen containing heterocycle having central &agr;2-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine.

    摘要翻译: 本发明涉及配制N-氧化物的化合物,其药学上可接受的加成盐和立体化学异构形式,其中每个R 1独立地是氢,卤素,C 1-6烷基,硝基,羟基或C 1-4烷氧基; Alk是C1-6烷二基; n为1或2; p为0,1或2; D是具有中枢性α2-肾上腺素受体拮抗剂活性的任选取代的单环,双环或三环含氮杂环。 它还涉及它们的制备,包含它们的组合物及其作为药物的用途。